The article presents 2-year pilot results of a multicenter, randomized, controlled trial of prostamol-UNO effects on symptoms progression, quality of life, tolerance and safety in patients with early prostatic adenoma. The drug was used in a single dose 320 mg/day for 36 months. Prostamol-UNO efficacy in arrest of the symptoms progression and quality of life was assessed with the use of IPSS and QoL (BS) questionnaires. Measurements were also made of changes in Qmax, urine volume, residual urine, size of the prostate.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
prostatic adenoma
8
symptoms progression
8
progression quality
8
quality life
8
[efficacy safety
4
safety prostamol-uno
4
prostamol-uno treatment
4
treatment patients
4
patients initial
4
initial symptoms
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!